经鼻高流量氧疗在慢性阻塞性肺疾病急性高碳酸血症性呼吸衰竭患者中的应用:一项多中心研究
这项多中心、前瞻性、分析性观察性病例系列研究在阿根廷5个ICU开展(2018年8月至2019年9月),纳入40例≥18岁、中至极重度慢阻肺、因高碳酸血症性急性呼吸衰竭入住ICU的患者,其中62.5%为重度慢阻肺。经鼻高流量氧疗(high-velocity nasal insufflation)作为一线通气支持实施1小时后,呼吸频率较基线下降27%(29 vs 21次/分;p<0.001),Paco2下降(57 vs 52 mm Hg[7.6 vs 6.9 kPa];p<0.001)。18%患者治疗失败,该组患者第一小时内呼吸频率、pH和Paco2无显著变化。作者结论认为经鼻高流量氧疗是降低此类患者呼吸频率的有效工具,早期评估和后续监测临床及血气参数可能有助于预测结局。
要点
- 40例慢阻肺急性高碳酸血症性呼吸衰竭患者经鼻高流量氧疗1小时后呼吸频率由29次/分降至21次/分(下降27%;p<0.001)。
- 同一小时后Paco2由57 mm Hg降至52 mm Hg(7.6 vs 6.9 kPa;p<0.001)。
- 18%患者经鼻高流量氧疗失败;失败组第一小时内呼吸频率、pH和Paco2无显著变化。
- 纳入患者中62.5%为重度慢阻肺,研究在阿根廷5个ICU开展。
适用人群与场景
- ≥18岁、中至极重度慢性阻塞性肺疾病、因高碳酸血症性急性呼吸衰竭入住ICU的患者(阿根廷5个ICU,2018年8月至2019年9月)。
处置流程与药物剂量
- 经鼻高流量氧疗通过鼻导管实施,采用high-velocity nasal insufflation,作为一线通气支持。
研究设计与关键结果
- 研究类型:多中心、前瞻性、分析性观察性病例系列研究;5个ICU;40例患者;62.5%为重度慢阻肺。
- 经鼻高流量氧疗第一小时后呼吸频率较基线显著下降27%(29 vs 21次/分;p<0.001)。
- 经鼻高流量氧疗第一小时后Paco2显著下降(57 vs 52 mm Hg[7.6 vs 6.9 kPa];p<0.001)。
- 经鼻高流量氧疗失败率18%;失败组第一小时内呼吸频率、pH和Paco2无显著变化。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、分析性观察性病例系列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,经鼻高流量氧疗(high-velocity nasal insufflation)是降低此类慢阻肺急性高碳酸血症性呼吸衰竭患者呼吸频率的有效工具。
- 作者认为,早期测定和后续监测临床及血气参数可能有助于预测结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the effect of high-flow oxygen implementation on the respiratory rate as a first-line ventilation support in chronic obstructive pulmonary disease patients with acute hypercapnic respiratory failure.
DESIGN: Multicenter, prospective, analytic observational case series study.
SETTING: Five ICUs in Argentina, between August 2018 and September 2019.
PATIENTS: Patients greater than or equal to 18 years old with moderate to very severe chronic obstructive pulmonary disease, who had been admitted to the ICU with a diagnosis of hypercapnic acute respiratory failure, were entered in the study.
INTERVENTIONS: High-flow oxygen therapy through nasal cannula delivered using high-velocity nasal insufflation.
MEASUREMENTS AND MAIN RESULTS: Forty patients were studied, 62.5% severe chronic obstructive pulmonary disease. After the first hour of high-flow nasal cannula implementation, there was a significant decrease of respiratory rate compared with baseline values, with a 27% decline (29 vs 21 breaths/min; p < 0.001). Furthermore, a significant reduction of Paco2 (57 vs 52 mm Hg [7.6 vs 6.9 kPa]; p < 0.001) was observed. The high-flow nasal cannula application failed in 18% patients. In this group, the respiratory rate, pH, and Paco2 showed no significant change during the first hour in these patients.
CONCLUSIONS: High-flow oxygen therapy through nasal cannula delivered using high-velocity nasal insufflation was an effective tool for reducing respiratory rate in these chronic obstructive pulmonary disease patients with acute hypercapnic respiratory failure. Early determination and subsequent monitoring of clinical and blood gas parameters may help predict the outcome.
参考来源
- Plotnikow GA, Accoce M, Fredes S, et al. High-Flow Oxygen Therapy Application in Chronic Obstructive Pulmonary Disease Patients With Acute Hypercapnic Respiratory Failure: A Multicenter Study. Crit Care Explor. 2021. PMID: 33615235. doi:10.1097/CCE.0000000000000337
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。